{"id":51230,"date":"2017-03-20T15:26:13","date_gmt":"2017-03-20T15:26:13","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=51230"},"modified":"2022-11-30T13:48:36","modified_gmt":"2022-11-30T18:48:36","slug":"joe-reilly-to-present-drug-and-alcohol-employee-testing-webinar","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/joe-reilly-to-present-drug-and-alcohol-employee-testing-webinar\/","title":{"rendered":"Joe Reilly to Present Drug and Alcohol Employee Testing Webinar"},"content":{"rendered":"\n<p>The Clear Law Institute is featuring a webinar presentation By Joe Reilly, Founder of National Drug Screening. On Thursday, May 25th at 3pm EST, Mr Reilly will be presenting the webinar, &#8220;Drug and Alcohol Testing of Employees.&#8221; Drug and alcohol abuse in the workplace has been a major issue for many businesses and employers are continually working to address this problem. Prior to beginning drug and alcohol testing, there are some requirements that employers must know and understand about implementing a drug and alcohol workplace policy. On May 25, 2017, Clear Law Institute will be holding a webinar for employers to learn about regulatory requirements and options that they may have for maintaining a <strong>drug-free and alcohol-free workplace<\/strong>.<\/p>\n\n\n\n<p>The program is $199 per person but through National Drug Screening you can<br><em><strong>save 35% off the registration price by using the promo code SPKR35<\/strong>&nbsp;<\/em>at checkout.&nbsp;<strong><a href=\"https:\/\/clearlawinstitute.com\/ce\/shop\/webinars\/on-demand-webinars\/drug-and-alcohol-testing-of-employees-062819\/\" target=\"_blank\" rel=\"noreferrer noopener\">Click Here to register<\/a>.<\/strong><\/p>\n\n\n\n<p>The course will provide detailed information on:<\/p>\n\n\n\n<ul>\n<li>The five components of a drug-free workplace program<\/li>\n\n\n\n<li>Drug testing options \u2013 Beyond the general 5-panel test<\/li>\n\n\n\n<li>Regulatory issues, including DOT regulations<\/li>\n\n\n\n<li>Medical and recreational marijuana issues<\/li>\n\n\n\n<li>Post-Accident testing and worker\u2019s compensation claims<\/li>\n\n\n\n<li>Effective drug testing while lessening exposure to liability<\/li>\n<\/ul>\n\n\n\n<p>This program will take place from 3:00 PM to 4:15 PM and will be presented by the president of National Drug Screening, Joe Reilly. Mr. Reilly also serves as the president of Joe Reilly &amp; Associates, Inc., a senior compliance officer for USA Mobile Drug Testing, Inc member of the board of directors for the Drug &amp; Alcohol Testing Industry Association (and former Chairman of the Board).<\/p>\n\n\n\n<p>This course has been approved for 1.25 general recertification credit hours towards PHR, SPHR, and GPHR recertification through the HR certification institute. This course is also valid for 1.25 Professional Development Credits.<\/p>\n\n\n\n<p>The program is $199 per person but through National Drug Screening you can&nbsp;<em><strong>save 35% off the registration price by using the promo code SPKR35<\/strong>&nbsp;<\/em>at checkout.&nbsp;<strong><a href=\"https:\/\/clearlawinstitute.com\/ce\/shop\/webinars\/on-demand-webinars\/drug-and-alcohol-testing-of-employees-062819\/\" target=\"_blank\" rel=\"noreferrer noopener\">Click Here to register<\/a>.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Clear Law Institute is featuring a webinar presentation By Joe Reilly, Founder of National Drug Screening. On Thursday, May 25th at 3pm EST, Mr Reilly will be presenting the webinar, &#8220;Drug and Alcohol Testing of Employees.&#8221; Drug and alcohol abuse in the workplace has been a major issue for many businesses and employers are [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":52983,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"51391,51535,50935,50870,50901,50862","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51230"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=51230"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51230\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/52983"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=51230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=51230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=51230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}